Megan H Cleveland, Ioannis L Karageorgos, John P Marino, Michael J Tarlov, Katharina S Yandrofski, Rebecca A Zangmeister, Zvi Kelman
{"title":"Recommended nomenclature convention for the NISTCHO cell line and its product monoclonal antibody, cNISTmAb.","authors":"Megan H Cleveland, Ioannis L Karageorgos, John P Marino, Michael J Tarlov, Katharina S Yandrofski, Rebecca A Zangmeister, Zvi Kelman","doi":"10.1080/19420862.2025.2490789","DOIUrl":null,"url":null,"abstract":"<p><p>NISTCHO is a Chinese hamster ovary (CHO) cell line expressing the same amino acid sequences as the heavy and light chains of the National Institute of Standards and Technology (NIST) monoclonal antibody [Reference Material (RM) 8671 NISTmAb]. NISTCHO was generated by MilliporeSigma to be developed by NIST as a RM to support biomanufacturing research and innovation, method development and qualification, and pre-competitive research collaboration. The RM cell line, denoted as RM 8675 NISTCHO, Clonal CHO-K1 Cell Line Producing cNISTmAb, is of interest to the biopharmaceutical and biomanufacturing industries, regulatory and government agencies, and academic institutions. In contrast to other NIST RMs, however, which are typically discrete and finite, the NISTCHO is a living RM that can be propagated, expanded, and used repeatedly to express the non-originator NISTmAb product, cNISTmAb. Therefore, a uniform naming convention should be adopted by the user community to best track the origins of materials (the cell line and products) used in studies derived from the RM 8675 NISTCHO. Here, we provide a naming convention for the derivatives of the RM 8675 NISTCHO and the cNISTmAb produced by these NISTCHO derivatives and recommend these naming conventions for adoption by the scientific community.</p>","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2490789"},"PeriodicalIF":5.6000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005425/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"mAbs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19420862.2025.2490789","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
NISTCHO is a Chinese hamster ovary (CHO) cell line expressing the same amino acid sequences as the heavy and light chains of the National Institute of Standards and Technology (NIST) monoclonal antibody [Reference Material (RM) 8671 NISTmAb]. NISTCHO was generated by MilliporeSigma to be developed by NIST as a RM to support biomanufacturing research and innovation, method development and qualification, and pre-competitive research collaboration. The RM cell line, denoted as RM 8675 NISTCHO, Clonal CHO-K1 Cell Line Producing cNISTmAb, is of interest to the biopharmaceutical and biomanufacturing industries, regulatory and government agencies, and academic institutions. In contrast to other NIST RMs, however, which are typically discrete and finite, the NISTCHO is a living RM that can be propagated, expanded, and used repeatedly to express the non-originator NISTmAb product, cNISTmAb. Therefore, a uniform naming convention should be adopted by the user community to best track the origins of materials (the cell line and products) used in studies derived from the RM 8675 NISTCHO. Here, we provide a naming convention for the derivatives of the RM 8675 NISTCHO and the cNISTmAb produced by these NISTCHO derivatives and recommend these naming conventions for adoption by the scientific community.
期刊介绍:
mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.